Business:
AAV capsid Gene Therapy
Drug notes:
13+ additional undisclosed programs RD ALS, Friedreich's ataxia, Parkinson's, rare neurological disease, CNS diseases, undisclosed
About:
Voyager Therapeutics is advancing delivery modalities for gene therapies. Many gene therapies are in development, yet delivery of the therapy is still a major limitation. AAVs are a popular choice but require high doses and have off-target effects. Voyager is using its TRACER screening platform to enhance AAV capsids’ specificity and ability to target desired cells and tissues. Voyager’s AAVs also pass the blood-brain barrier, offering the potential to cure neurological diseases. Initial non-human primate data demonstrate the selectivity of TRACER-derived capsids to target the CNS and cardiac muscle. These capsids may enable single-dose treatment for a broad spectrum of diseases.
Senior/Principal Research Associate, AAV Capsid En... Lexington, MA|15 days ago
Senior Director, Corporate and Business Developmen... Lexington, MA|16 days ago
Associate Director, Vector Production Lexington, MA|17 days ago
Senior/Principal Research Associate, In Vivo Lexington, MA|22 days ago
Scientist II/Sr. Scientist, In-Vivo Pharmacology Lexington, MA|24 days ago
Associate Director, Program Management Lexington, MA|44 days ago
Senior Director, Clinical Supply Chain Lexington, MA|75 days ago
Director, Protein Science Lexington, MA|100+ days ago
Director, Oligo Chemistry & Bioconjugation Lexington, MA|100+ days ago
Voyager Prospects - Submit for future opportunitie... Cambridge/Lexington, MA|100+ days ago